Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer

Published:2018-02-01 Issue:2 Volume:4 Page:217
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Fox Josef J.¹,Gavane Somali C.¹,Blanc-Autran Estelle²,Nehmeh Sadek³,Gönen Mithat⁴,Beattie Brad³,Vargas Hebert A.¹,Schöder Heiko¹,Humm John L.³,Fine Samson W.⁵,Lewis Jason S.¹,Solomon Stephen B.¹,Osborne Joseph R.¹,Veach Darren¹,Sawyers Charles L.⁶,Weber Wolfgang A.¹,Scher Howard I.⁷⁸,Morris Michael J.⁷⁸,Larson Steven M.¹

Affiliation:

1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Nuclear Medicine, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France

3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York

4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

6. Human Oncology Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York

7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

8. Department of Medicine, Weill Cornell Medicine, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance;Cancer Heterogeneity and Plasticity;2024-08-25

2. [18F]FDHT tumour imaging for predicting response to treatment based on androgen receptor;Journal of Radioanalytical and Nuclear Chemistry;2024-08-14

3. Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway;Molecular Oncology;2024-08-02

4. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer;Med;2024-08

5. A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer;Molecular Cancer Therapeutics;2024-06-12